Concord Biotech Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.4K Cr
Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level.
From Concord Biotech's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,548
Market Cap
₹16.4K Cr
P/E Ratio
57.8
How does Concord Biotech rank in Pharmaceuticals & Biotechnology?
Compare Concord Biotech against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Concord Biotech — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹278 Cr, net profit ₹68 Cr.
Full financials →📊 Revenue & Sales Performance
- →Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years.
- →Growth is expected from both API and formulation segments, with API contributing around 80% and formulations about 20%.
- →API third-party sales are anticipated to grow at around 10-12%, while formulations, especially due to capacity ramp-up, are expected to grow north of 40% to achieve overall 20%+ company growth.
- →Injectables are expected to gradually contribute more, with asset turnovers of INR 300-600 crores and a phased ramp-up over 5 years contributing about 6% growth.
- →Growth is volume-driven with stable pricing; no significant price hikes anticipated.
- →Capacity utilization at key units (Unit 1: 78%, Unit 3: 35%) is expected to increase, supporting growth.
- →Growth opportunities exist in fermentation APIs and CDMO space, including peptides, but these are in early stages.
📈 Profitability & Margins
🏗️ Capital Expenditure Plans
- →Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized.
- →No significant growth capex expected for FY '24-'25; only maintenance capex of around INR 15-20 crores per annum anticipated.
- →Future capex may be considered if new opportunities arise within or adjacent to fermentation APIs, either in-house or through procurement.
- →Strategic investment: Concord will acquire a 26% equity stake in CleanMax Private Limited and CleanMax Enviro Energy Solutions (renewable energy provider in Gujarat).
- →This investment supports sustainability goals by powering the Dholka plant with 6.6 MW wind and 3.3 MW DC solar capacity, reducing carbon footprint and energy costs.
- →Injectable plant is scheduled to begin commercial production this quarter, with expected ramp-up and contribution to revenue and profitability in the coming years.
💰 Fundraising & Capital Structure
- →As of the latest update in February 2025, Concord Biotech has indicated that CapEx is largely complete, particularly for the injectable unit with INR 225 crores spent, which will be capitalized.
- →For FY '25, there is no expectation of growth CapEx; only maintenance CapEx around INR 15-20 crores per annum is planned.
- →The company mentioned that if new opportunities arise in fermentation or adjacent areas, they may consider in-house or external investments, but no specific plans for new fundraising through debt or equity were disclosed.
- →Overall, there is no explicit mention of any current or imminent fundraising via debt or equity in the provided material.
📋 Order Book & Pipeline
- →Concord Biotech has a strong order book position as of Q3 FY '25.
- →Certain opportunities are currently active and anticipated to convert within the quarter.
- →Some customer orders faced delays, pushing certain order executions from Q3 to Q4.
- →There is a possibility, though less likely, that some orders may move beyond Q4 into Q1.
- →The company remains confident in execution based on January and February performance.
- →Management is actively working on new customer acquisitions and expanding market share.
- →No specific numeric order book value disclosed, but execution visibility is positive with ongoing momentum.
Key Metrics
Frequently Asked Questions
What were Concord Biotech Q3 FY25 results?
Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level.
What is Concord Biotech share price analysis?
Concord Biotech currently shows a neutral. The stock trades at a P/E of 57.8 with a market cap of ₹16,438 Cr. Investors should review the full earnings analysis for detailed insights.
Is Concord Biotech planning capital expenditure?
Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized.
Keep Concord Biotech on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.